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Abstract: Radiomics, via the extraction of quantitative information from conventional radiologic
images, can identify imperceptible imaging biomarkers that can advance the characterization of
coronary plaques and the surrounding adipose tissue. Such an approach can unravel the underlying
pathophysiology of atherosclerosis which has the potential to aid diagnostic, prognostic and, thera-
peutic decision making. Several studies have demonstrated that radiomic analysis can characterize
coronary atherosclerotic plaques with a level of accuracy comparable, if not superior, to current
conventional qualitative and quantitative image analysis. While there are many milestones still to be
reached before radiomics can be integrated into current clinical practice, such techniques hold great
promise for improving the imaging phenotyping of coronary artery disease.
Keywords: machine learning; radiomics; coronary computed tomography angiography; acute
coronary syndrome; atherosclerosis; plaque; peri-coronary adipose tissue
1. Introduction
Coronary artery disease (CAD) remains a leading cause of death despite advances
in primary and secondary prevention strategies [1]. Acute coronary syndrome (ACS)
comprising myocardial infarction (MI) and unstable angina is responsible for much of
its mortality and morbidity burden. Vascular inflammation is considered a key driver of
atherosclerotic plaque formation and destabilization resulting in ACS [2]. Randomized
studies demonstrate a residual inflammatory risk even after the aggressive lowering of
low-density lipoprotein cholesterol [3]. The landmark CANTOS trial showed that targeting
interleukin-1β with the monoclonal antibody canakinumab reduced recurrent cardiovas-
cular event rates, hence validating the inflammatory hypothesis of atherosclerosis [4].
This has led to a burgeoning research interest in the non-invasive detection of vascular
inflammation, which has important implications for cardiovascular risk stratification and
the initiation of appropriate risk reduction strategies.
Conventional tests that rely on circulating inflammatory biomarkers (e.g., high-
sensitivity C-reactive protein and pro-inflammatory cytokines) are not directly related
to the process of atherogenesis, and not specific enough to identify coronary inflamma-
tion [5]. Advanced imaging tests such as sodium-fluoride positron emission tomography
are costly and not widely available, limiting their applicability in clinical practice [6].
Coronary computed tomography angiography (CCTA) is rapidly becoming a first-line
diagnostic test in the investigation of suspected CAD [7–9]. It offers a unique non-invasive
modality to image and assess the coronary lumen, plaque, and perivascular tissue [10].
Currently, CCTA interpretation predominantly relies on visual assessment which disregards
the large volume of three-dimensional datasets recording each pixel’s radiodensity and
their relationship to each other. Recently, improvements with CCTA’s imaging quality and
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access to high-performance computing have led to the development of cardiac computed
tomography radiomics, introducing the field of artificial intelligence (AI) to cardiovascular
imaging. Radiomics is the process of extracting numerous quantitative features from a
given region of interest to create large data sets in which each abnormality is described by
hundreds of parameters. Data mining is the process of finding new, meaningful patterns
and relationships between the different variables. Machine learning can also be applied to
the analysis of radiomics parameters. From these results, novel imaging biomarkers may
be identified that can increase the diagnostic accuracy of CCTA and expand our knowledge
of the underlying pathologic processes.
The objective of this review is to first introduce the current state of AI in modern CCTA,
followed by an overview of the coronary radiomics analysis workflow, current literature
regarding the use of radiomics techniques in the assessment of coronary inflammation, and
finally the current challenges of incorporating radiomics into clinical practice.
2. Artificial Intelligence, Machine Learning and Big Data
Modern cardiovascular medicine generates a vast amount of biomedical, imaging,
and clinical data as part of patient care delivery. The high dimensionality of data poses
demanding analytical challenges but offers rich opportunities for improved discovery. The
term big data refers to extremely large datasets which cannot be analyzed, interpreted, or
stored efficiently using conventional data-processing techniques [11]. In healthcare, this
includes “omic” data (genomics, proteomics, or lipidomics), biometrics from streaming
mobile devices, clinical data from electronic health records, and image-derived information.
Traditional statistical methods cannot efficiently handle and learn from such elaborate
data sets to develop diagnostic and predictive models for assisting clinical decision-making.
Artificial intelligence refers to the use of computational techniques to perform tasks that
are characteristic of human intelligence, such as visual perception, pattern recognition,
planning, problem-solving, and decision making [12]. AI is being increasingly applied
in cardiovascular imaging for image segmentation, automated measurements, and risk
stratification [13,14].
Machine learning (ML) is a subset of AI which uses computer algorithms with the
ability to automatically learn to perform a task and improve from experience by being
exposed to a large amount of data, without being explicitly programmed in decision
making [15]. ML methods complement and extend existing statistical methods, providing
tools and algorithms to understand patterns from large, complex, and heterogeneous data.
Although conventional statistical methods are capable of both discovery and prediction,
ML methods are suitable and generalizable across a variety of data types and offer analyses
and interpretation across complex variables [16]. Additionally, ML techniques typically
rely on fewer assumptions and provide superior and more robust predictions.
Common types of ML algorithms include supervised and unsupervised [17]. The
selection of the right model often relies on the operator’s expertise, the nature of the dataset,
and the purpose of the final AI system [18]. Supervised learning algorithm is most commonly
employed in CCTA application, which uses a labeled dataset to predict the desired outcome.
This involves the iterative selection, processing, and weighting of individual features to
learn the underlying patterns within the data that best fit the given outcome. Limitations
of supervised learning include the need for large, labeled training datasets and validation
datasets. It is also often time-consuming due to the need for the manual labeling of large
amounts of data. Furthermore, supervised algorithms are limited to predicting known
outcomes. In unsupervised learning, unlabeled data are used to predict unknown outcomes,
and the algorithm must discover inherent patterns within the dataset. Such techniques
include principal component analysis and the wide array of clustering algorithms (e.g.,
“k-means” or hierarchical clustering) which cluster data into groups based on similarity.
The major challenge in unsupervised learning is difficulty in identifying the initial cluster
pattern (how many clusters there are, and their respective boundaries), which may lead
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to overfitting of the model to the dataset. Hence, these models require validation in
multiple cohorts.
3. Radiomics: Bringing CCTA Imaging into the Age of Artificial Intelligence
CCTA is now recognized as the pivotal non-invasive diagnostic imaging modality
of choice for cardiovascular risk stratification and the assessment of stable and unstable
cardiovascular patients [19,20]. The strength of CCTA lies in its ability to reliably exclude
coronary stenosis and [21,22], to directly visualize the vessel wall and plaque morphol-
ogy [23]. Over the past years, CCTA technology has developed at unprecedented speed
while data analysis and image interpretation progressed at a slower pace as its diagnostic
potential is burdened by a certain degree of subjective visual assessment and inter-reader
variability. For example, even among expert readers, the inter-reader reproducibility of
high-risk plaque features is highly variable (κ range 0.15–0.34) [24]. Furthermore, it is
unable to detect the finer characteristics of high-risk plaques such as macrophage activity,
neovascularization, plaque rupture, and plaque erosion, which can all be detected by
optical coherence tomography (OCT) [25].
CT radiodensity of the vascular tissue has been shown to be a good surrogate marker of
histological composition as correlated with intravascular ultrasound (IVUS) [26]. Therefore,
CCTA’s capability to non-invasively acquire isotropic three-dimensional data creates a
unique opportunity to analyze complex spatial image patterns using radiomics. This
refers to the process of extracting a large number of quantitative imaging features from
a given region of interest to create big data in which each abnormality is characterized
by hundreds of parameters extending far beyond those that can be characterized by the
human eye [27]. The quantitative features are calculated using dedicated software, which
accepts the image datasets as inputs. Following feature extraction, data mining and ML
approaches are used to find new, meaningful patterns between the different parameters to
identify novel imaging biomarkers which may reflect the underlying pathophysiology of a
tissue. Additionally, radiomics offers mathematic objectivity with the use of quantitative
image parameters instead of qualitative markers to express different lesion characteristics.
The transition from qualitative to quantitative radiomics assessment was initiated
by oncoradiology and has proven to be a valuable tool [28]. Several studies have shown
radiomics to improve the diagnostic accuracy, staging, and grading of cancer, response
assessment to treatment, and predict clinical outcomes [29–36]. CCTA radiomics faces its
unique technical challenges as atherosclerotic lesions have a significantly smaller number
of voxels for analysis than tumors as well as having complex geometric shapes.
4. Overview of Coronary Radiomics Workflow
4.1. Step 1: Images Acquisition
The coronary radiomics workflow begins with the CCTA image, which is represented
as a three-dimensional dataset of different attenuation values using semi-parametric cali-
brated Hounsfield Units (HU). Each of the different tissues involved absorbs radiation to a
different extent and thus, they are depicted as having different attenuation values on CT.
As such, each voxel is a separate measurement of how much radiation is absorbed in the
given volume and correlates with the underlying biology.
4.2. Step 2: Region-of-Interest Segmentation
Next, a region-of-interest (ROI) is defined so that only information related to the lesion
can be extracted. The coronary artery needs to be segmented at its proximal and distal ends
of interest as well as determining the inner and the outer vessel wall boundaries. Then, the
HU values of the voxels need to be discretized into a given number of groups, as voxels
with the identical value rarely occur in medical imaging (Figure 1).
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Figure 1. Pipeline for segmentation of region-of-interest.
To date, segmentation of the coronary artery is done either manually or semi-automatically
with dedicated software such as QAngioCT, 3D Slicer, or AutoPlaque [37–39]. Automatic
lumen and vessel contours can be manually edited if needed. Software such as 3D Slicer has
incorporated an installable plugin for the open-source PyRadiomics package for integrated
radiomics analyses. Manual and semi-automated image segmentation can be time-consuming
and prone to observer bias and variability. Therefore, studies using such segmentation tech-
nique should assess for intra- and inter-observer reproducibility of the derived radiomic
features and exclude non-reproducible features from further analyses. Deep learning-based
image segmentation is yet to be available for coronary assessment but it is rapidly emerging
for many different organs [40]. This has the advantage of avoiding intra- and inter-observer
variability of radiomic features. However, the generalizability of trained algorithms is a major
limitation currently, and applying those algorithms on a different dataset often results in com-
plete failure. Thus, further research is needed for the development of robust and generalizable
algorithms for automated image segmentation.
4.3. Step 3: Radiomic Features Extraction
Feature extraction refers to the calculation of feature descriptors to quantify the char-
acteristics of the grey levels within the ROI. Since many different ways and formulas exist
to calculate those features, adherence to the Image Biomarker Standardization Initiative
guideline is recommended [41]. These radiomic features can be broadly grouped into four
major categories: (1) shape based, (2) intensity based, (3) texture based, and (4) transformed
based (Table 1). In practice, feature extraction means simply running the dedicated software
package and waiting for the computation to be finished.






























Shape-based metrics are more widely used in clinical routines and easily comprehensible.
It describes the shape of the traced ROI and its geometric properties such as volume and
the maximum diameter along different orthogonal planes.
Intensity-based metrics describe the distribution of individual voxel values but without
accounting for their spatial relationships. These are histogram-based properties reporting
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the average and variation (mean, median, maximum, and minimum values of the voxel
intensities on the image). The shape of the distribution can be quantified by skewness
(asymmetry) and kurtosis (flatness). Lastly, the heterogeneity of the sample values can be
quantified by uniformity and randomness (entropy).
Texture-based metrics are obtained by calculating the statistical inter-relationship be-
tween neighboring voxels [42]. They provide a measure of the spatial arrangement of the
voxel intensities, and hence of intra-lesion heterogeneity. The gray-level co-occurrence
matrix (GLCM) is a matrix whose row and column numbers represent gray values, and the
cells contain the number of times corresponding gray values are in a certain relationship
(angle, distance), as shown in Figure 2. Features calculated on GLCM include entropy
(related to heterogeneity), energy (also defined as angular second moment, also describes
heterogeneity of an image), contrast (measures local variation), cluster shade (sensitive to
heterogeneity), homogeneity, dissimilarity, and correlation [43].
Figure 2. Example calculation of radiomic texture features. Whereas the gray-level co-occurrence
matrix (GLCM) relies on pixel pairs, the gray-level run-length matrix (GLRLM) relies on runs, and the
gray-level size zone matrix (GLSZM) relies on areas of neighboring pixels with the same gray-level.
Gray-level run-length matrix (GLRLM) quantifies consecutive voxels with the same
intensity along fixed directions (Figure 2) [44]. It is represented as a two-dimensional matrix
in which each element describes the number of times a gray level appears consecutively
in the direction specified. Gray-level size zone matrix (GLSZM) is a matrix in which the
elements at row r and column s store the number of zones (the connected voxels with the
same gray level) with gray level r and size s (Figure 2).
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An image is represented in the spatial domain where a vast number of pixel/voxel
values are distributed along with the spatial coordinates. The image can be transformed into
the frequency domain by representing the pattern and rate at which the image intensity
values change along with spatial directions. One method is the wavelet transformation
which decomposes the data into high- and low-frequency components. At high frequency,
the wavelets can capture discontinuities, ruptures, and singularities in the original data.
At low frequency, the wavelets characterize the coarse structure of the data to identify the
long-term trends. Thus, numerous hidden and significant temporal features of the original
data can be extracted while improving the signal-to-noise ratio of imaging studies [45].
4.4. Step 4: Feature Selection/Dimensionality Reduction
The process of feature extraction will yield a large number of radiomics features.
Using all the extracted features in a statistical model would lead to overfitting, where
the model corresponds too closely to the training dataset, such that it picks up noise and
performs poorly in internal and external validation. The purpose of feature selection is to
identify the optimal set of radiomics features to be taken forward for model building and
aim to include model features that are most informative and robust while removing those
that are unstable or provide repetitive information.
Robustness of features can be assessed through test–retest, with the removal of those
with poor repeatability. Many radiomics features will be expected to reflect duplicate
information (for example, the diameter, surface area, and volume of a sphere shape),
and these will need to be identified and to select only those that are most informative.
Cluster analysis aims to create groups of similar features (clusters) with high intra-cluster
redundancy and low inter-cluster correlation. This is often depicted by a cluster heat map
as shown in Figure 3. A single feature may be selected from each cluster as representative
and used in the following association analysis. Principal component analysis through
different methods reduces the extracted features to a subset that provides nearly as much
information as the whole feature set [46].
4.5. Step 5: Model Building
Once the final sets of radiomics features are identified, they can be used as predic-
tor/discriminatory variables of the classification model. The model building starts by using
a training set consists of example cases (training examples) with input vectors consists
of the final set of radiomic features which are paired with desired model output labeled
with the known outcome. The algorithm determines how much weight (importance) is
placed on each feature to achieve optimal model performance. In some cases, logistic
regression will be adequate to address a simple classification problem. More commonly,
machine learning algorithms (random forest, neural networks, or least absolute shrinkage
and selection operator) are used to train different models; from these, the model with the
best performance is selected.
4.6. Step 6: Validation
Before the predictive model can be applied in a clinical setting, the model’s stability
and reproducibility must be assessed. The first step in model validation is internal cross-
validation which uses an internal dataset that has not mixed with the training data during
the model building or feature selection process.
External validation with an independent external dataset is important for the assessment
of model performance and generalizability. The models are able to compute a probability
of belonging to a class and not only a discrete value. Model performance is thus assessed
using measures of sensitivity, specificity, receiver operating curves, and area under the
curve (AUC).
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Figure 3. Graphic representation of radiomic feature clustering. Each radiomic feature was compared with all other features
using linear regression analysis. Features were clustered based on the absolute values of the correlation coefficient of
the corresponding regression models and plotted along both axes (ranging from 0 to 1 with greater values are shown in
yellow with increasing intensity). In this example, the yellow blocks along the diagonal identify the clusters containing the
highly correlated radiomic features. The first cluster in the top left corner demonstrated very high redundancy for radiomic
features (represented by the high homogeneity of the yellow blocks). The blue blocks visualize the low correlation observed
between the radiomic features. Adapted from Rizzo et al. [47].
5. Current Literature on Radiomics Analysis for Coronary Artery Disease
Recently, there has been increasing research interest in CCTA radiomics to identify
new biomarkers associated with plaque vulnerability (Table 2). This has been facilitated by
the ever-growing size of CCTA datasets and registries, and its unique capability to capture
reliable qualitative and quantitative information of coronary plaques and the surrounding
adipose tissue on the entire coronary tree.
5.1. Radiomics Assessment of Coronary Plaques
Coronary atherosclerotic plaques consist of distinct histological components with
different attenuation values on CTA; each voxel is a separate measurement of the amount
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of radiation absolved in the given volume. This has enabled the assessment of plaque
morphology in vivo, and several qualitative and quantitative imaging biomarkers are
known to associate with adverse cardiovascular events. Advanced atherosclerotic plaques
that are prone to cause ACS are characterized by large lipid-rich necrotic cores, increased
amounts of inflammatory cells, and thin fibrous caps [48]. Invasive imaging modalities,
such as IVUS and OCT offer sub-millimeter spatial resolution and can depict distinct
morphologic markers of plaque vulnerability, which have been validated by histology and
clinical investigations [49,50]. While CCTA might not have sufficient spatial resolution,
its unique ability to non-invasive image atherosclerotic lesions holds great potential to
identify high-risk plaques. Four distinct plaque characteristics (positive remodeling, low
attenuation, spotty calcification, and napkin-ring sign) derived from CCTA have been
linked to major adverse cardiovascular events [10]. However, these visually detectable
adverse plaque characteristics show only a modest correlation with IVUS- or OCT-derived
features [51].
The first study to perform radiomics analysis of the coronary artery demonstrated the
feasibility and potential clinical utility of CCTA radiomics to reliably identify plaques with
the napkin-ring sign [37]. This high-risk plaque phenotype is composed of a thin fibrotic cap
above a lipid-rich necrotic core, an extracellular conglomerate within the intima induced
by necrosis and apoptosis of lipid-laden macrophage foam cells [55]. This qualitative CT
feature is defined as a plaque cross-section with a central area of low CT attenuation in
contact with the lumen, which is surrounded by a ring-shaped higher attenuation tissue.
Kolossváry et al. compared 30 patients with plaques with the napkin-ring sign to 30
matched patients with plaques without such sign but with similar degrees of calcification,
luminal obstruction, localization, and acquisition parameters. The study showed that
20.6% of radiomic features showed significantly higher discrimination of the napkin-ring
sign than conventional quantitative measures. Furthermore, parameters incorporating the
spatial distribution of voxels (GLCM, GLRLM, and geometry-based parameters) have a
better predictive value than first-order statistics.
In a subsequent study, the radiomics-based ML model has been shown to outperform
conventional and histogram-based CCTA analysis in differentiating between early and
advanced atherosclerotic lesions identified by histologic cross-sections [52]. Analyzing
21 coronary arteries obtained ex vivo from seven male donors, lesions were considered
advanced if early fibroatheroma, late fibroatheroma, or thin-cap atheroma was found. Eight
different radiomics-based ML models were tested, and the least angles regression models
provided the best discriminatory power on the training set. The radiomics-based ML model
outperformed expert visual assessment for the identification of advanced lesions (AUC
0.73 vs. 0.65, p = 0.04).
More recently, sodium-fluoride positron emission tomography (NaF18-PET) has been
introduced as a radionuclide imaging modality to identify inflammation and microcal-
cifications in coronary atherosclerotic plaques [56]. Vascular calcification is viewed as
a cellular response to a necrotic, inflammatory microenvironment and also a marker of
plaque metabolic activity [57]. Detecting areas of microcalcification at its earliest stages
can help to identify high-risk lesions, but these do not become detectable on CCTA until
late in the natural history of atherosclerosis [56,58]. In a retrospective analysis, Kolossváry
et al. were able to demonstrate that CCTA radiomic parameters (compared to conventional
CT parameters) consistently correlates better with the invasive and radionuclide imaging
markers of high-risk plaques [53]. Among the calculated radiomic parameters, textural fea-
tures (fractal dimensions) correlated best with attenuated plaque identified by IVUS (AUC
0.72, CI 0.65–0.78) and thin-cap fibroatheroma by OCT (AUC 0.80, CI 0.72–0.88). While
the surface of high attenuation voxels correlated best with NaF18-positivity (AUC 0.87,
CI 0.82–0.91). These microcalcifications were most likely recorded as voxels with higher
HU values but were visually imperceptible. Furthermore, since the microcalcifications
are not grouped in one cluster like the calcified plaques, the surface area of these high
attenuation voxels will be larger.
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Table 2. Studies examining the relationship between CT-derived radiomics parameters of coronary plaques and PCAT with coronary atherosclerosis.
Study Input Region-of-Interestfor Radiomics Analysis Outcomes Assessed Study Design Main Findings
Kolossváry et al.
[37] (2017) Coronary artery plaques Napkin-ring sign
30 plaques with napkin-ring sign vs. 30
matched plaques without.
Best radiomic parameter: short-run low-gray-level
emphasis (AUC 0.92, CI 0.82–0.996).
Best conventional parameter: mean plaque attenuation
(AUC 0.77, CI 0.64–0.88).
Kolossváry et al.




311 early atherosclerotic lesions (adaptive
intimal thickening, pathologic intimal
thickening, and fibrous plaque).
134 advanced atherosclerotic lesions (early
fibroatheroma, late fibroatheroma, and
thin-cap fibroatheroma).
Lease angles regression machine learning
model used.
Radiomics-based machine learning
(AUC 0.73 CI 0.63–0.84).
Visual-based plaque attenuation pattern
(AUC 0.65, CI 0.56–0.73).
Histogram-based low attenuation plaque area
(AUC 0.55, CI 0.42–0.68).
Histogram-based average HU
(AUC 0.53, CI 0.42–0.65).
Kolossváry et al.




25 patients (44 lesions) undergoing CCTA,
NaF18-PET, IVUS, and OCT.
IVUS attenuated plaque
Best radiomic parameter: fractal box counting dimension
of high attenuation voxels (AUC 0.72, CI 0.65–0.78)
Best conventional parameter: non-calcified plaque volume
(AUC 0.59, CI 0.57–0.62)
OCT thin-cap fibroatheroma
Best radiomic parameter: fractal box counting dimension
of high attenuation voxels (AUC 0.80, CI 0.72–0.88)
Best conventional parameter: presence of low attenuation
(AUC 0.66, CI 0.58–0.73)
NaF18-PET positivity
Best radiomic parameter: surface of high attenuation
voxels (AUC 0.87, CI 0.82–0.91)
Best conventional parameter: presence of two high risk
features (AUC 0.65, CI 0.64–0.66)
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Table 2. Cont.
Study Input Region-of-Interestfor Radiomics Analysis Outcomes Assessed Study Design Main Findings
Oikonomou et al.
[38] (2019)










events (composite endpoint of
cardiac mortality and non-fatal
myocardial infarction)
Study 3
Acute myocardial infarction vs.
stable CAD
Study 1
167 patients underwent CCTA followed by
cardiac surgery where cardiac adipose tissues
were obtained.
Study 2
5487 patients underwent CCTA as part of the
SCOT-HEART trial or the CRISP-CT study.
Out of this cohort, 101 patients experienced
MACE within 5 years of CCTA.
Random forest machine learning model used.
Study 3
44 patients with AMI vs. 44 matched controls
with stable CAD.
Study 1
TNFA expression is best associated with
wavelet-transformed mean attenuation.
COL1A1 and CD31 expression best associated with
texture-based metrics.
Study 2
Radiomics-based ML model significantly improved MACE
prediction when added to traditional risk stratification
that included risk factors, coronary calcium score,
coronary stenosis, and CCTA HRP features
(∆[C-statistic] = 0.126, p < 0.001).
Study 3
Fat radiomics profile is higher in patients with AMI
compared to the matched controls (p < 0.001).
Lin et al. [39] (2020) PCAT of proximal RCA Myocardial infarction vs.stable CAD vs. No CAD
60 patients with acute MI were matched with
60 controls.
Extreme gradient boosting machine learning
model used.
20.3% of the radiomic parameters differed significantly
between MI patients and controls. 16.5% differed between
patients with MI vs. stable CAD. No difference between
patients with stable CAD vs. control.
Kolossváry et al.
[54] (2021) Coronary artery plaques




300 patients with subclinical CAD who had
serial CCTA at least 1 year apart. 168 (56%)
had an increased ASCVD score. 226 (75.3%)
had HIV infection. 174 (58%) reported
cocaine use.
Elevated ASCVD score was associated with 8.2% of
radiomic features, HIV infection was associated with 1.3%
and cocaine use was associated with 23.7%. Parameters
associated with elevated ASCVD score or cocaine use and
HIV infection did not overlap.
AMI: acute myocardial infarction, ASCVD: atherosclerotic cardiovascular disease, AUC: area under the curve, CAD: coronary artery disease, CCTA: coronary computed tomography angiography, CD31:
cluster of differentiation 31, CI: confidence interval, COL1A1: collagen type 1 alpha 1, CVD: cardiovascular disease, HIV: human immunodeficiency virus, HRP: high-risk plaque, HU: Hounsfield unit, IVUS:
intravascular ultrasound, LAD: left anterior descending, MACE: major adverse cardiovascular events, MI: myocardial infarction, ML: machine learning, NaF18-PET: sodium fluoride-18 positron emission
tomography, OCT: optical coherence tomography, PCAT: peri-coronary adipose tissue, RCA: right coronary artery, TNFA: tumor necrosis factor alpha.
Cells 2021, 10, 879 12 of 17
It has been shown that both conventional and nonconventional cardiovascular risk
factors (such as cocaine use and HIV infection) affect the different pathways of atheroscle-
rosis progression at a molecular level [59–61]. Cocaine use impairs nitric oxide release and
increases the levels of cell and leukocyte adhesion molecules, causing the migration of
white blood cells into the intimal layers. HIV infection causes the chronic activation of the
innate immune system, which results in increased levels of inflammatory cytokines (such
as interleukin-6, CD14, and CD163) and activation of white blood cells resulting in chronic
vasculopathy. In a study involving 300 patients with subclinical CAD, Kolossváry et al.
demonstrated that cocaine use, HIV infection and elevated atherosclerotic cardiovascular
disease risk were each associated with their own distinct sets of radiomics parameters
(23.7%, 1.3%, and 8.2%, respectively) [54].
5.2. Radiomics Assessment of Pericoronary Adipose Tissue
Beyond plaque, it is now established that the coronary artery wall and its pericoro-
nary adipose tissue (PCAT) interact in a bidirectional manner [58]. Exposure of PCAT to
pro-inflammatory cytokines suppress the differentiation of pre-adipocytes while triggering
their proliferation, resulting in numerous smaller adipocytes with fewer intracellular lipid
droplets [58]. This creates a gradient of differing PCAT density with a lipid-rich/less-
aqueous phase adjacent to a non-diseased vessel to lipid-poor/more-aqueous phase ad-
jacent to an inflamed artery. This inflammatory process was paralleled by reduced gene
expression of the adipocyte differentiation markers PPARγ, CCTAT/enhancer binding
protein α (CEBPA), and fatty acid binding protein-4 (FABP4).
Routine CT employs a Hounsfield Units scale of attenuation (reduction in signal),
which can be used as a non-invasive measure of adipose tissue (AT) quality [62]. AT is
detected within the window of −190 to −30 HU [63,64], and experimental animal studies
have shown lower HU to be associated with more lipid-dense AT [65]. The link between
biopsy-proven PCAT inflammation and CT attenuation was established in a landmark
study by Antonopoulos et al. [58]. On ex vivo CT scans of AT explants and in vivo
CCTA, they demonstrated an inverse association of PCAT attenuation with histological
adipocyte size and degree of adipocyte differentiation, with higher PCAT attenuation
(less negative HU) reflecting smaller adipocytes with lower lipid content. This surrogate
measure of coronary inflammation has been shown to predict plaque progression and
cardiac mortality in patients undergoing CCTA for suspected CAD and to differentiate
stages of CAD [15,57,66,67]. However, PCAT attenuation is akin to an intensity-based
parameter that simply enumerates the average voxel intensity values, without considering
the spatial relationship among voxels.
Following on from their landmark study establishing the utility of PCAT attenuation,
Oikonomou et al. performed radiomics analysis of their original cohort of 167 patients [38].
The authors found that wavelet-transformed mean attenuation (an intensity-based metric)
was most correlated with the relative expression of TNF-α (a surrogate marker of inflam-
mation). Higher-order features (such as small area low gray-level emphasis, short-run
low gray-level emphasis, and informal measure of correlation) correlated with relative
expression of COL1A1 (a surrogate marker of fibrosis) and CD31 (a surrogate marker of
vascularity). The authors subsequently developed a ML model (random forest) using a
pool of 5487 patients who underwent CCTA from either the CRISP-CT study or the SCOT-
HEART trial [15,68]. The selected CCTAs were then randomly split into a training/internal
validation (80%) and an external validation set (20%). In total, 1391 radiomic features for
PCAT were included in the model, from 101 patients who presented with MACE at 5 years,
against 101 matched controls. Compared with established clinical risk prediction models,
the used algorithm was able to accurately discriminate cases over controls both in the vali-
dation study and when applied to the SCOT-HEART study population (∆C-statistic = 0.126,
p < 0.001). In the third part of their study, the authors have demonstrated that there is a
significant difference in the radiomics profile between their cohort of 44 patients with AMI
compared with 44 matched controls. Interestingly, in a subset of 16 patients who underwent
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repeat CCTA 6 months later, there was no significant change with the radiomics profile but
there was a significant decrease with the Fat Attenuation Index (intensity-based metrics).
On the other hand, radiomics analysis of PCAT performed by Lin et al. showed that
textural (GLCM and GLRLM) and geometric, rather than intensity-based radiomic features,
to be most significant in distinguishing patients with and without MI [39]. Consistent with
the previous study, the authors found no significant change in the radiomics profile at 6
months of follow-up. This study utilized a state-of-the-art boosted ensemble ML algorithm
(XGBoost) to create a predictive model for identifying patients with MI [69]. Radiomic
features provided incremental value over and above PCAT attenuation and clinical features
(including hs-CRP and cardiac risk factors) for discriminating patients with MI.
6. Challenges and Future Perspectives
Radiomics is an exciting new discipline with the potential to increase our knowledge
in CCTA imaging inform downstream decision making. However, like most emerging
techniques, there is a need for standardized acquisition protocols and data analysis tech-
niques to provide a robust framework for radiomics analysis. Several studies have shown
that imaging parameters, reconstruction settings, or segmentation algorithms all affect
the radiomics signature of lesions (Table 3) [70–73]. Furthermore, it has been shown that
the variability caused by these changeable parameters is in the range or even greater
than the variability of radiomic features of tumor lesions [74]. To date, there are several
contributions that aim to facilitate standardization of radiomics implementation, and data
reporting [41,75,76].
Table 3. Potential factors limiting radiomic feature robustness, reproducibility, and classification performance.
Image Acquisition Reconstruction Segmentation andPost-Processing Feature Extraction
Model Building and
Validation
• Tube voltage and
milliamperage
• Slice thickness
















• Size of the ROI
• HU discretization






• Population of the
validation sets
HU: Hounsfield unit, ROI: region of interest.
Additionally, the current radiomics analysis workflow remains technically complex
and time-consuming to be a useful addition to the daily clinical routine. There is a need to
develop user-friendly automated software solutions capable of implementing radiomics
without increasing the clinical load.
In the future workflow, a useful radiomics tool should seamlessly integrate into the
clinical radiological workflow and be incorporated into or interfaced with the existing
RIS/PACS system. Such system should provide a deep learning-based fully automated
segmentation tool with the option for manual correction. Known important radiomics
features could then be displayed alongside other quantitative imaging biomarkers and the
images themselves. The clinician could then use all the available information to precisely
predict the patient’s cardiovascular risk and prescribed personalized preventive therapy.
Lastly, CCTA radiomics is an emerging research tool and there is a need for prospective
data, multi-center studies, and cost analysis before it has the potential for implementation
into clinical workflow. It is also vital to have large datasets available to optimize external
validation and enhance the generalizability of the prediction models. This can be facilitated
by cooperation between academic institutions.
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7. Conclusions
For many years, CCTA was regarded as a rule-out test for obstructive coronary artery
disease due to its excellent negative predictive value. Radiomics presents a novel quantita-
tive image analysis technique with the potential to greatly augment CCTA phenotyping
in a manner that enhances our diagnostic and predictive capabilities. CCTA radiomics
features may also provide unique insights into the pathophysiology of atherosclerosis at the
tissue level and aid understanding of the mechanism of the “vulnerable plaque”. However,
current clinical data remains in its infancy and further effort is needed to standardize
radiomics analysis protocols among different centers. Moreover, several technical aspects
need to be further investigated to ensure the reliability and generalizability of the radiomic
features. Furthermore, before radiomics can become of the daily clinical routine, further
effort is required to render such technology sufficiently user friendly and time effective.
Despite its present technical challenges, there is great promise for radiomics to facilitate an
individualized assessment of cardiovascular biology and risk.
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